The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Research and development expenses of BioNTech SE from 2022 to 2024, by type (in million euros)
R&D expenses of BioNTech by type 2022-2024
In 2024, total R&D expenses of biotech company BioNTech SE stood at some 2.25 billion U.S. dollars, of which over two billion euros were spent on non-COVID-19 products. On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you BioNTech
Overview
5
- Premium Statistic Global biotech drug sales estimate 2012-2024
- Basic Statistic Percentage of global pharmaceutical sales by technology 2016-2030
- Basic Statistic Major pharmaceutical products by sales worldwide 2025
- Premium Statistic Forecasted revenue of mRNA market revenue worldwide 2021-2035
- Premium Statistic Daily stock price indexes of selected pharmaceuticals firms 2020-2025
Key figures
5
Competitors
5
COVID-19 vaccine
6
- Premium Statistic Pfizer/BioNTech COVID-19 vaccines delivered by country income group 2021
- Premium Statistic Shareholdings at select COVID-19 vaccine companies by investor 2021
- Premium Statistic Select COVID-19 vaccine pricing and funding as of August 2020
- Basic Statistic Forecasted COVID-19 vaccine share of total mRNA revenues globally 2021-2035
- Basic Statistic COVID-19 vaccinations administered in the U.S. as of April 2023, by manufacturer
- Basic Statistic Comparison of select COVID-19 vaccines 2022, by efficacy
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
BioNTech, & U.S. Securities and Exchange Commission. (March 10, 2025). Research and development expenses of BioNTech SE from 2022 to 2024, by type (in million euros) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 18, 2026, from /statistics/1300613/r-and-d-expenses-biontech-by-type/
BioNTech, und U.S. Securities and Exchange Commission. "Research and development expenses of BioNTech SE from 2022 to 2024, by type (in million euros)." Chart. March 10, 2025. ÌÇÐÄÆƽâ°æ. Accessed July 18, 2026. /statistics/1300613/r-and-d-expenses-biontech-by-type/
BioNTech, U.S. Securities and Exchange Commission. (2025). Research and development expenses of BioNTech SE from 2022 to 2024, by type (in million euros). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 18, 2026. /statistics/1300613/r-and-d-expenses-biontech-by-type/
BioNTech, and U.S. Securities and Exchange Commission. "Research and Development Expenses of Biontech Se from 2022 to 2024, by Type (in Million Euros)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 10 Mar 2025, /statistics/1300613/r-and-d-expenses-biontech-by-type/
BioNTech & U.S. Securities and Exchange Commission, Research and development expenses of BioNTech SE from 2022 to 2024, by type (in million euros) ÌÇÐÄÆƽâ°æ, /statistics/1300613/r-and-d-expenses-biontech-by-type/ (last visited July 18, 2026)
Research and development expenses of BioNTech SE from 2022 to 2024, by type (in million euros) [Graph], BioNTech, & U.S. Securities and Exchange Commission, March 10, 2025. [Online]. Available: /statistics/1300613/r-and-d-expenses-biontech-by-type/
Advertisement